You are living a dark speculative fantasy.
I’ve been here many years, and when asked many years ago where an artisan novel autologous biologic such as this might be best developed and launched, I said the UK, for several reasons. It may have been even before I started posting here. Long before Brexit or anyone suggested the FDA may or may not be supportive.
Years ago, people were still scared this technology would cause a massive autoimmune reaction and quickly kill the patient. All large pharma, as the early patents will educate you, missed this technology because they were frightened of potential liability or daunted by the long process toward developing mass production for an autologous therapy.
Still other large pharmaceutical simply didn’t want to go toward a path that might one day lead to a complete cure — given the right development and combinations.
(Note: Iova and Adap do not utilize the same technology.)
Market Data 
Markets 
AI
